Peptide Initiative

Peptides · Peptide comparison

Prostamax vs Testagen

Prostate-specific tetrapeptide bioregulator (Lys-Glu-Asp-Pro) that normalizes prostatic epithelial differentiation through chromatin remodeling at prostate gene promoters, restores the proliferation-apoptosis balance disrupted in benign prostatic hyperplasia, and reduces inflammatory cytokine signaling in aging prostate tissue

Testicular tetrapeptide bioregulator (Lys-Glu-Asp-Gly) that normalizes HPG axis signaling through DNA minor groove binding at testicular gene promoters, increases testosterone synthesis by restoring Leydig cell function, and modulates neuroendocrine feedback loops controlling gonadotropin secretion in aging males

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeProstamax0.01–100 mcg/kgTestagen10–10 mg
FrequencyProstamaxOnce dailyTestagenOnce daily
AdministrationProstamaxSublingual (enteric-coated capsules)TestagenSublingual (enteric-coated capsules)
Cycle lengthProstamax12+ weeksTestagen12+ weeks
Onset speedProstamaxGradual (3-4 weeks)TestagenGradual (3-4 weeks)
Evidence levelProstamaxLimited human trialsTestagenLimited human trials

Efficacy

Benefit ratings

Prostate Health

Prostamax94%
TestagenNo recorded rating

Urinary Function

Prostamax88%
TestagenNo recorded rating

Tissue Inflammation

Prostamax82%
TestagenNo recorded rating

Testosterone Support

ProstamaxNo recorded rating
Testagen92%

Male Aging Health

ProstamaxNo recorded rating
Testagen88%

Reproductive Function

ProstamaxNo recorded rating
Testagen85%

Technical data

Compound specifications

Prostamax

Molecular formula
C20H33N5O9
Molecular weight
487.5 g/mol
Half-life
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability
CAS number
Not publicly registered

Testagen

Molecular formula
C17H29N5O9
Molecular weight
447.4 g/mol
Half-life
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to testicular gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to short tetrapeptide structure
CAS number
Not publicly registered

Protocols

Dosing compared

Prostamax

Intramuscular

  • 0.01-100 mcg/kgOnce daily · 10-40 daysDose from a single-institute patent report in 35 chronic-prostatitis patients [6]. The wide range reflects dose-finding within that single report.

Oral

  • ~10 mgOnce daily · 10-30 day courseCapsule form reflecting bioregulator product labeling and practice [1].

Testagen

Subcutaneous

  • 5-10 mgOnce daily · 10-day courseInjectable course used in practice; repeat after 3-6 months [1].

Oral

  • 10 mg (2 x 5 mg capsules)Once daily · 10 days (maintenance) up to 30 days (therapeutic) per courseKhavinson cytogen taken as enteric capsules; repeat course every 3-6 months [1].

Applications

Best suited for

Prostamax

Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Testagen

Age-related testosterone decline (andropause) requiring physiological restoration rather than replacement
Testagen is particularly well-suited for individuals focused on age-related testosterone decline (andropause) requiring physiological restoration rather than replacement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
HPG axis normalization in aging males with suboptimal hormonal signaling
Testagen is particularly well-suited for individuals focused on hpg axis normalization in aging males with suboptimal hormonal signaling. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male reproductive health
Testagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male reproductive health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Testicular geroprotection — preserving Leydig and Sertoli cell function during aging
Testagen is particularly well-suited for individuals focused on testicular geroprotection — preserving leydig and sertoli cell function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Prostamax

Common

  • Injection site reaction
  • Mild fatigue
  • Urinary frequency changes
  • Mild headache

Uncommon

  • Mild pelvic discomfort

Serious

  • No documented serious adverse effects

Testagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Libido fluctuation

Uncommon

  • Mild acne or skin oiliness

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Prostamax

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.

Contraindications

  • Known or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
  • Severe urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
  • Concurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms

Testagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Testagen (lyophilized peptide complex) lacks published human safety data—all information derives from unpublished manufacturer data and theoretical extrapolation from rat studies. As an androgen secretagogue, it carries class risks including erythrocytosis (elevated red blood cell count), liver enzyme elevation, lipid profile unfavorable changes (reduced HDL, increased LDL), and prostate-related effects including urinary obstruction and potential malignancy acceleration. Cardiovascular risk including hypertension and increased thrombotic events are theoretical concerns based on androgen class pharmacology.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, glycine)
  • Hormone-sensitive cancers (prostate, testicular) — potential stimulation of androgen-dependent pathways
  • Pregnancy and breastfeeding (female partners) — not applicable for direct use but consider reproductive implications
  • Severe hepatic or renal impairment — peptide metabolism may be altered

Decision guide

Which is right for you?

Prostamax

Choose Prostamax if…

  • Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
  • Prostate geroprotection — preserving prostatic epithelial function during aging
  • Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
  • Comprehensive Khavinson bioregulator protocols targeting male genitourinary health

Testagen

Choose Testagen if…

  • Age-related testosterone decline (andropause) requiring physiological restoration rather than replacement
  • HPG axis normalization in aging males with suboptimal hormonal signaling
  • Comprehensive Khavinson bioregulator protocols targeting male reproductive health
  • Testicular geroprotection — preserving Leydig and Sertoli cell function during aging